NCT07634094 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07634094
Title	Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer
Recruitment	Not yet recruiting
Gender	female
Phase	Phase II
Variant Requirements	No
Sponsors	Kalinski, Pawel, MD, PhD
Indications	ovary epithelial cancer ovarian carcinosarcoma fallopian tube carcinoma peritoneum cancer fallopian tube carcinosarcoma
Therapies	Alpha 2 Interferon + alphaDC1 + Celecoxib + Cisplatin + Paclitaxel + Pembrolizumab + Rintatolimod Alpha 2 Interferon + Celecoxib + Cisplatin + Paclitaxel + Pembrolizumab + Rintatolimod
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
UMPC Hillman Cancer Center		Pittsburgh	Pennsylvania	15232	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07634094Clinical Trial Detail